Loading organizations...
§ Private Profile · Newark, CA, USA
clinical-stage biopharmaceutical company developing novel inhaled therapies for cardiac arrhythmias, especially PAF.
Founded in 2009 by Carlos Schuler and Grace E. Colón, InCarda Therapeutics is a Newark, California-based clinical-stage biopharmaceutical company specializing in novel inhaled therapies for cardiovascular diseases, such as paroxysmal atrial fibrillation (PAF). Their lead product is an orally inhaled flecainide formulation for rapid conversion of recent-onset, symptomatic PAF to sinus rhythm, delivered via a portable nebulizer for self-administration. It has secured significant investment, including a $42 million oversubscribed Series B in 2018 and an initial $30 million Series C close, from investors such as Deerfield Management, HealthCap, Innoviva, and Morningside Ventures. Dr. Myles Greenberg was appointed President and CEO in December 2024, succeeding interim CEO Carlos Schuler and previous CEO Robert Lisicki. With 29 employees, InCarda advances its innovative approach to treating cardiovascular conditions.
InCarda Therapeutics has raised $77.0M across 3 funding rounds.
InCarda Therapeutics has raised $77.0M in total across 3 funding rounds.
InCarda Therapeutics has raised $77.0M across 3 funding rounds. Most recently, it raised $30.0M Series C in October 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 21, 2020 | $30M Series C | George Bickerstaff | Deerfield Management, HealthCap, Morningside | Announced |
| Nov 8, 2018 | $42M Series B | Johan Christenson, Alan Colowick | Asset Management Ventures, Andrew ElBardissi, MD, Reenie Mccarthy | Announced |
| Apr 28, 2015 | $5M Series A | Reenie Mccarthy | — | Announced |
InCarda Therapeutics has raised $77.0M in total across 3 funding rounds.
InCarda Therapeutics's investors include George Bickerstaff, Deerfield Management, HealthCap, Morningside, Johan Christenson, Alan Colowick, Asset Management Ventures, Andrew ElBardissi, MD, Reenie McCarthy.